โ† All deals

Pathos AI, Inc.

BiotechnologyAIBiotechnologyDrug Development
๐Ÿ“ Chicago, IL, USAโ€ข Founded 2022
StreetZero Signal 85
Be the first to signal interest

About Pathos AI, Inc.

Pathos AI is an AI-enabled biotechnology company focused on re-engineering drug development by combining computational approaches across multimodal real-world data and patient-derived biological models. The clinical-stage company partners with pharmaceutical firms to advance precision medicines, with a pipeline that includes experimental oncology assets in-licensed from Novo Nordisk, Prelude Therapeutics and Rain Oncology. It operates from Chicago and maintains the website www.pathos.com.

LATEST FUNDINGPrivate Placement
$237.5M
Announced 2026-11-19
TOTAL RAISED$669M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Pathos AI, Inc..

Free plan includes 3 full deal profiles every month.

Investors

Not disclosed in the source filing. Form D filings do not list investors โ€” StreetZero surfaces them from news where available.

Key highlights

  • Raised $237.5 million via private placement in biotechnology.
  • Platform combines AI with real-world data and patient-derived models for precision oncology.
  • Pipeline includes assets sourced from Novo Nordisk and Prelude Therapeutics.
  • Total funding reached $669 million after multiple rounds including a $365 million Series D.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account